Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.48 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299433 | 0.91 | CD274 (0.48) | FFAR1CD274PDCD1LG2PDCD1 | |
| SCHEMBL14943922 | 0.82 | FFAR1 (0.54) | FFAR1CD274PDCD1LG2PDCD1 | |
| SCHEMBL2303818 | 0.81 | CYP1A2 (0.48) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2301629 | 0.81 | FFAR1 (0.58) | FFAR1CD274PDCD1 | |
| SCHEMBL2298241 | 0.81 | FFAR1 (0.48) | FFAR1CD274PDCD1LG2PDCD1 | |
| SCHEMBL2300745 | 0.80 | FFAR1 (0.47) | FFAR1CD274PDCD1LG2PDCD1 | |
| SCHEMBL2302843 | 0.79 | CD274 (0.46) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2300364 | 0.77 | PPARA (0.56) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2305001 | 0.76 | CD274 (0.45) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2299400 | 0.76 | FFAR1 (0.46) | FFAR1CD274PDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | claimed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | claimed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | claimed |
| WO-2016149299-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160271149-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. | 2016-09-22 | — | — | US | disclosed |
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | PPARD, PPARA, PPARG | FFAR1 10/4885CD274 2428/4885PDCD1LG2 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.